A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
- 1 January 2014
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 121 (8) , 849-859
Abstract
Increased levels of extracellular glutamate and hyperactivation of glutamatergic receptors in the basal ganglia trigger a critical cascade of events involving both intracellular pathways and cell-to-cell interactions that affect cell viability and promote neuronal death. The ensemble of these glutamate-triggered events is responsible for excitotoxicity, a phenomenon involved in several pathological conditions affecting the central nervous system, including a neurodegenerative disease such as Parkinson’s disease (PD). PD is an age-related disorder caused by the degeneration of dopaminergic neurons within the substantia nigra pars compacta, with a miscellaneous pathogenic background. Glutamate-mediated excitotoxicity may be involved in a lethal vicious cycle, which critically contributes to the exacerbation of nigrostriatal degeneration in PD. Since excitotoxicity is a glutamate-receptor-mediated phenomenon, growing interest and work have been dedicated to the research for modulators of glutamate neurotransmission that might enable new therapeutic interventions to slow down the neurodegenerative process and ameliorate PD motor symptoms.Keywords
This publication has 103 references indexed in Scilit:
- NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptorsCell Death & Disease, 2013
- Alpha-synuclein: from secretion to dysfunction and deathCell Death & Disease, 2012
- Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegenerationCell Death & Differentiation, 2012
- Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neuronsProceedings of the National Academy of Sciences, 2012
- A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamicsCell Death & Disease, 2011
- Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disordersNature Reviews Neuroscience, 2010
- Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's diseaseBritish Journal of Pharmacology, 2010
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonismMovement Disorders, 2008
- Neurotransmitter receptor heteromers and their integrative role in ‘local modules’: The striatal spine moduleBrain Research Reviews, 2007
- Glutamate release from activated microglia requires the oxidative burst and lipid peroxidationJournal of Neurochemistry, 2007